Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214852 | 0.86 | LPAR2 (0.42) | LPAR2CD38ALDH1A1TP53HTT | |
| SCHEMBL15214864 | 0.85 | LPAR2 (0.40) | LPAR2CD38ALDH1A1GPR119HTT | |
| SCHEMBL2477392 | 0.85 | MAPK1 (0.41) | LPAR2CD38MAPK1GPR119HTT | |
| SCHEMBL10176265 | 0.75 | LMNA (0.45) | LPAR2ALDH1A1MAPK1HTT | |
| SCHEMBL2476576 | 0.72 | LMNA (0.43) | LPAR2CD38HTT | |
| SCHEMBL27410321 | 0.72 | LPAR2 (0.51) | LPAR2MAPK1 | |
| SCHEMBL30808044 | 0.69 | PDPK1 (0.48) | LPAR2ALDH1A1THRBCYP17A1 | |
| SCHEMBL22750924 | 0.67 | LMNA (0.51) | ALDH1A1MAPK1TP53HTT | |
| SCHEMBL10176274 | 0.65 | ALDH1A1 (0.49) | ALDH1A1MAPK1DGAT1KIF11 | |
| SCHEMBL14478872 | 0.63 | FGFR1 (0.60) | ALDH1A1MAPK1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | LPAR2 1461/4885CD38 727/4885GRIN2C 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.